Additional Insights: Androgen Receptor Inhibitor Adverse Events

ASCO® 2024 Insights: Dr. Daniel Petrylak on ARV-766Подробнее

Manipulating the Androgen Axis: New Agents in mHSPC and CRPCПодробнее

Larry Karsh - How do I choose Androgen Biosynthesis Inhibitor, Androgen Receptor Antagonist, or bothПодробнее

Androgen Receptor AntagonistsПодробнее

Dr. Morris on Safety Profiles of AR Inhibitors in Prostate CancerПодробнее

Metastatic Prostate Cancer: Androgen Receptor BiologyПодробнее

Managing M0 CRPC Patients on AR InhibitorsПодробнее

Real-world insights of ARSIs and ADTs in mCSPCПодробнее

IDEF Educational Series Modulating the Androgen sebum Pathway with an Androgen Receptor InhibitorПодробнее

Dr. Higano on the Toxicity of Androgen Receptor Inhibitors in CRPCПодробнее

Basic Science Forum: "A new perspective on androgen receptor action in estrogen receptor-α..."Подробнее

Manipulating The Androgen Axis | Radionuclide Therapy And Bone HealthПодробнее

Dr. Agarwal on Androgen Receptor Inhibitors for Prostate CancerПодробнее

Manipulating the Androgen Axis: New Agents in mHSPC and CRPCПодробнее

Study Sheds Light on Mislabeling, Adulteration of Selective Androgen Receptor ModulatorsПодробнее

Androgen Receptor Antagonists - Dana Rathkopf, MDПодробнее

Garnick - Review of the New Standard in Treatment and Global IssuesПодробнее

PCa Commentary - nmCRPC and Androgen Receptor Inhibition: Enzalutamide, Apalutamide and DarolutamideПодробнее

Targeting the Androgen Receptor: Past, Present and FutureПодробнее